Gene Sequencing in Genetic Disorders: From Mutation to Protein Dysfunction to Therapy

Knowing a gene's DNA sequence enables a direct path from variant to mechanism to treatment.

Workflow

  1. Variant Identification: Compare affected vs. unaffected genomes (WES, WGS, panels) → find SNVs, indels, CNVs, splice variants.
  2. Gene-Level Annotation: Predict effect on protein (missense, nonsense, frameshift, splice, regulatory). Tools: SIFT, PolyPhen, CADD, REVEL.
  3. Protein Impact: Model 3D structure (AlphaFold, homology) → assess stability, active site, protein-protein interfaces, localization signals.
  4. Functional Validation: In vitro assays (enzyme activity, channel conductance, binding), cellular models (patient iPSCs, CRISPR-edited lines), animal models.
  5. Pathway Integration: Place protein in pathways (e.g., CFTR in Cl⁻ transport, airway surface liquid). Identify downstream consequences.
  6. Therapeutic Targeting:
    • Correctors/potentiators (CFTR modulators for cystic fibrosis).
    • Antisense oligonucleotides (nusinersen for SMA).
    • Gene therapy (AAV vectors).
    • Small molecules stabilizing mutant protein.
  7. Personalized Medicine: Genotype guides drug choice, dosing, monitoring.

Example: Cystic Fibrosis

  • CFTR gene sequenced → >2000 variants classified (F508del most common).
  • F508del → misfolding → ER retention → no channel at membrane.
  • Correctors (lumacaftor, tezacaftor, elexacaftor) + potentiator (ivacaftor) → restore function.
  • Therapy now genotype-specific (e.g., Trikafta for ≥1 F508del).

Sequence → structure → function → therapy: the paradigm of precision medicine.

Genetic Disorders - Related Articles